Loading
PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Acute lymphoblastic leukaemia and 2 more.
Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G protein coupled receptor activation to PIP3 production.
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes clinical 0.67, affected pathway 0.61, literature 0.99, genetic association 0.30, somatic mutation 0.23).
In plain words · PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Acute lymphoblastic leukaemia and 2 more.
PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Acute lymphoblastic leukaemia and 2 more.
Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3).
No product in this corpus aims at PIK3CG yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PIK3CG: RNA group enriched (bone marrow 41 nTPM, lymphoid tissue 18 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia); Open Targets associates it with 2 specific cancer types at or above 0.5 (B-cell chronic lymphocytic leukemia, follicular lymphoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PIK3CG tissue; Open Targets ENSG00000105851 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Stoyanov et al, Science, 1995, "Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase". Source.
Sources: HGNC HGNC:8978 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P48736 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000105851 (association with cancer (MONDO_0004992) 0.54; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.58, B-cell chronic lymphocytic leukaemia 0.57, non-Hodgkin lymphoma 0.61, follicular lymphoma 0.55, leukaemia 0.58 (GraphQL API, CC0))
Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarisation and migration by regulating the spatial accumulation of PIP3 and by regulating the organisation of F-actin formation and integrin-based adhesion at the leading edge. Location: Cytoplasm; Cell membrane (UniProt). Locus 7q22.3 (HGNC).
RNA: group enriched (bone marrow 41 nTPM, lymphoid tissue 18 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Adrenal gland, Appendix, Bone marrow, Breast, Duodenum, Endometrium and more.
No cancer stained high; medium in breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA PIK3CG tissue · HPA PIK3CG pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PIK3CG" OR ABSTRACT:"PIK3CG" OR TITLE:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma" OR ABSTRACT:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma" OR TITLE:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform" OR ABSTRACT:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PIK3CG, not a curated reading list.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Follicular lymphoma, Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).